secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001104659-23-127772
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm plans Phase 3b NurOwn trial, SPA submission in Feb 2024 after ADCOM setback
--------------------------------------------------------------------------------

- CEO Chaim Lebovits letter outlines Phase 3b trial as most expedient path to FDA approval for NurOwn ALS therapy.
- Company expects to submit clinical protocol, SAP, and SPA request to FDA in February 2024; FDA response within 45 days.
- Type A meeting held Dec 6, 2023; FDA engaged and recognized unmet need in ALS, says BrainStorm.
- Funding strategies being explored; company aims to boost stock price by April to maintain NASDAQ listing, preferring organic support over reverse split.
- Dr. Menghisteab Bairu appointed to Audit Committee replacing Dr. June S. Almenoff, effective Dec 18, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923127772/0001104659-23-127772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923127772/tm2333401d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-127772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer